ArticleAmerican journal of translational research2019
Inhibitory effects of catalpol coordinated with budesonide and their relationship with cytokines and Interleukin-13 expression.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Catalpol: an natural multifunctional iridoid glycoside with promising therapeutic properties.Frontiers in molecular biosciences · 2026Review
- Multifaceted therapeutic potentials of catalpol, an iridoid glycoside: an updated comprehensive review.Inflammopharmacology · 2025Review
- Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4Pharmaceutical biology · 2021Article
- Article
- Effects of catalpol on asthma by airway remodeling via inhibiting TGF-β1 and EGF in ovalbumin-induced asthmatic mice.American journal of translational research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, the molecular mechanism for inhibitory effect of Catalpol coordinated with Budesonide (BUD) on allergic airway inflammation was investigated. A total of 30 adult SD rats were randomly divided into five groups, namely the positive control group, the model group, the Catalpol group, the BUD group, and the Catalpol+BUD group with 6 rats in each group, respectively. The pathologic changes of lung tissue were observed by HE stain method. The lung function of rats, the cell count, and the cytokine concentrations in bronchoalveolar lavage fluid (BALF) were detected. The levels of cytokines [interleukin-4 (IL-4), interleukin-5 (IL-5), and interferon gamma (IFN-γ)] in BALF were measured using enzyme-linked immunosorbent assay method. The expressions of Interleukin-13 (IL-13) and Eotaxin in lung tissue were measured by RT-PCR method. The total number of cells in the BALF of the group treated with Catalpol and BUD was significantly lower than the model group. The cytokines IL-5 and IL-4 exhibited a similar tendency: the concentrations of IL-4 and IL-5 for the Catalpol group were dramatically decreased compared with the model group. However, the IFN-γ concentration for the Catalpol and BUD groups were higher than the model group. After treatment with Catalpol+BUD, the eosinophils and neutrophils of the rats were further reduced, asthma-associated inflammation was obviously inhibited, IL-4 level was further decreased and IFN-γ level was further increased comparing the Catalpol group and the BUD group. Moreover, IL-13 expression was positively correlated with Eotaxin expression. The results indicated that Catapol could inhibit the expression of IL-13 and Eotaxin in the lung of asthmatic rats, which also exhibited a synergistically inhibitory effect with BUD on airway inflammation. It is suggested that Catalpol+BUD might be an effective and potential treatment for the clinical therapy of asthma.
Indexed as
Identifiers
31737193PMC6834495W2997922607What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.